Taylor M Ortiz MD

Oncology•Methuen, MA

Medical Director, Medical Oncology and Hematology, Medical Director, Oncology Clinical Research and Bioinformatics

Join to View Full Profile

5 Branch StSte 100Methuen, MA 01844
Phone+1 978-620-2020
Fax+1 978-620-2299

Summary

Dr. Taylor Ortiz is an oncologist in Indianapolis, IN and is affiliated with multiple hospitals in the area, including Franciscan Health Indianapolis, and Franciscan Health Lafayette East. He received his medical degree from Harvard Medical School and his Medical Oncology and Hematology training at the Dana-Farber Cancer Institute and Massachusetts General Hospital. He has been in practice 13 years. He is experienced in solid tumor oncology, hematologic oncology, with executive leadership experience including program development, recruiting, clinical informatics, and phase 2/3 clinical trials.

Education & Training

Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2007 - 2010
McGaw Medical Center of Northwestern UniversityResidency, Internal Medicine, 2004 - 2007
Harvard Medical SchoolClass of 2004

Certifications & Licensure

NH State Medical License 2010 - Present
IN State Medical License 2015 - 2025
MA State Medical License 2007 - 2025
IL State Medical License 2004 - 2007
American Board of Internal Medicine Hematology
American Board of Preventive Medicine Clinical Informatics

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification MOSAIQ EMR, Elekta, 2013

Clinical Trials

Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Start of enrollment: 2010 Oct 25
Completed
Phase 3
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery Start of enrollment: 2010 Jun 01
Active, not recruiting
Phase 3
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer Start of enrollment: 2011 Feb 14
Completed
Phase 3
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2014 Jan 15
ACTIVE_NOT_RECRUITING
PHASE3
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2014 Mar 10
ACTIVE_NOT_RECRUITING
PHASE3
Join now to see all

Publications & Presentations

PubMed

88 citations
The Introduction of Systematic Genomic Testing for Patients With Non-Small-Cell Lung Cancer
Stephanie Cardarella, Taylor M. Ortiz, Victoria A. Joshi, Mohit Butaney, David M. Jackman
Journal of Thoracic Oncology. 2012-12-01
KRAS mutation analysis helps to differentiate between pulmonary metastasis from colon adenocarcinoma in situ and primary lung adenocarcinoma.
Taylor M. Ortiz, David W. Cohen, Michael S. Kent, Pasi A. Jänne, Daniel B. Costa
Journal of Thoracic Oncology. 2011-01-01
64 citations
G-CSF is not necessary to maintain over 99% dose–intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis
Andrew M. Evens, Jeffrey Cilley, Taylor Ortiz, Mrinal M. Gounder, Nanjiang Hou
British Journal of Haematology. 2007-06-01

Press Mentions

Franciscan Health Lafayette to Break Ground on Cancer CenterJune 29th, 2022